This article is part of the PlexusDx Education Hub evidence-based guidance on GLP-1 therapies, weight management protocols, and the genetic variables that shape every metabolic decision
The doctor will no longer be the bottleneck
Validation: Jinguang Wang
doi: 10.3389/fendo.2024.1503905 Received 29 September 2024 Accepted 09 December 2024 Published 09 January 2025 Volume 15 - 2024 Edited by Weibin Bai, Jinan University, China Reviewed by Zia Ur Rehman, University of Agriculture, Pakistan Kamil Gill, Pomeranian Medical University, Poland Updates Copyright 2025 Saleh, Sallam, Elsuity, Dutta, Sengupta and Nasr
For instance, in August 2024, Eli Lilly and Company announced positive topline results from the SURMOUNT-1 trial, a three-year study evaluating the effectiveness and safety of tirzepatide (marketed as Zepbound and Mounjaro) administered once weekly for long-term weight management and delaying the progression to diabetes in adults with pre-diabetes and obesity or overweight
Investigating the optical and thermodynamic properties of 2D MoGe 2 P 4 : Potential material for photothermal therapy
